Breast density predicts endocrine treatment outcome in the adjuvant setting.
In their report, Kim and colleagues study the ability of changes in mammographic density over a period of 12 to 18 months to predict subsequent recurrence in 1,065 Korean women with oestrogen receptor-positive breast cancer. Based on 80 recurrences, a clear gradient for lower recurrence rates was seen among women with larger density reductions - with recurrence rates being more than twofold higher in women with no reduction compared with those presenting a reduction ≥10%. This extends previous work on predicting the effectiveness of tamoxifen in individual women from the preventive setting to the adjuvant setting, and also includes women treated with aromatase inhibitors, where a slightly larger effect was seen.
Jack
J
Cuzick
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000071060:Breast Density; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D042361:Mammary Glands, Human / Q000002:abnormalities*; D011379:Prognosis; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal